Nuformix (LSE:NFX) Capex-to-Revenue : 0.00 (As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Nuformix Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Nuformix's Capital Expenditure for the six months ended in Sep. 2022 was £0.00 Mil. Its Revenue for the six months ended in Sep. 2022 was £0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Nuformix Capex-to-Revenue Historical Data

The historical data trend for Nuformix's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuformix Capex-to-Revenue Chart

Nuformix Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Capex-to-Revenue

Get a 7-Day Free Trial

6.73

0.04

0.08

0.01

Nuformix Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
Capex-to-Revenue	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Nuformix's Capex-to-Revenue

For the Biotechnology subindustry, Nuformix's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuformix's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuformix's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nuformix's Capex-to-Revenue falls into.

Nuformix Capex-to-Revenue Calculation

Nuformix's Capex-to-Revenue for the fiscal year that ended in Mar. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0.05
	=	0.00

Nuformix's Capex-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Nuformix (LSE:NFX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Nuformix Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nuformix's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuformix (LSE:NFX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuformix PLC (LSE:NFX) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

1RT:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.nuformix.com

Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.